This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sabatolimab
- DrugBank Accession Number
- DB16322
- Background
Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Anti-tim-3 monoclonal antibody mbg453
- Anti-tim3 checkpoint inhibitor mbg453
- Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer
- Immunoglobulin g4-kappa, anti-(homo sapiens havcr2 (hepatitis a virus cellular receptor 2, t-cell immunoglobulin mucin family member 3, tim-3, tim3, timd3, cd366)), humanized monoclonal antibody
- Sabatolimab
- External IDs
- MBG 453
- MBG-453
- MBG453
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- ATC Codes
- L01FX19 — Sabatolimab
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3L7R886Y06
- CAS number
- 2252262-24-9
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1 2 Active Not Recruiting Supportive Care Myelodysplastic Syndrome 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia 1 2 Completed Treatment Myelodysplastic Syndrome 1 2 Recruiting Treatment Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 15, 2020 20:02 / Updated at February 21, 2021 18:55